CN107693844A - A kind of composition gels and application - Google Patents
A kind of composition gels and application Download PDFInfo
- Publication number
- CN107693844A CN107693844A CN201610639475.4A CN201610639475A CN107693844A CN 107693844 A CN107693844 A CN 107693844A CN 201610639475 A CN201610639475 A CN 201610639475A CN 107693844 A CN107693844 A CN 107693844A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- composition
- composition gels
- biodegradable material
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of composition gels and application, belong to regenerative medicine and biomedicine field.Said composition gel is mainly made up of Biodegradable material gel and stem cell.The composition gels of the present invention have the advantages of degradation cycle is lasting, stability is good, stem cell raw material sources are extensive.
Description
Technical field
It is more particularly to a kind of to be coagulated containing stem cell and Biodegradable material the present invention relates to a kind of composition gels and application
The composition gels of glue and application, belong to regenerative medicine and biomedicine field.
Background technology
Mesoderm and outer embryo of the mescenchymal stem cell (MSC, mesenchymal stem cells) from mesoderm growing early stage
Layer a kind of multipotential stem cell, the interstitial tissue that can be divided between cell and gain the name, have multi-lineage potential, hematopoiesis support
The concern of people is increasingly subject to the features such as promoting stem cell implantation, immunoregulation and self-replacation.Mescenchymal stem cell is wide
It is general to be distributed in marrow, periosteum, spongy bone, fat, synovial membrane, skeletal muscle, tire liver, deciduous teeth, umbilical cord, Cord blood, in vivo or body
Under outer specific inductive condition, it is more that fat, bone, cartilage, muscle, tendon, ligament, nerve, liver, cardiac muscle, endothelium etc. can be divided into
Kind histocyte, still has multi-lineage potential after continuous passage culture and freezen protective, preferable seed cell can be used as to use
In injuries of tissues and organs reparation caused by aging and lesion.
In terms of regenerative medicine, turn into the tissue of itself using Derived from Mesenchymal Stem Cells, permanent presence, length can be played
Phase moulding effect；Various population of stem cells under body can be activated in a dormant state, it is original because of aging or disease to substitute renewal
Histiocytic decline and aging, reach the recovery of tissue organ function caused by the factors such as rationality, strengthen the work of histoorgan
Property and original anti-tolerance, improve because of the cell and iuntercellular caused by the factors such as aging, between cell and extracellular matrix
Information transmission, strengthen and accelerate the effect such as each histiocytic succession of the old by the new, anti-aging, beauty, smoothing wrinkle can be played a part of.
Relevant stem cell is used for having had some researchs in terms of shaping and beauty.Chinese patent CN200610152104.X discloses one kind
Human soft tissue filler for injection being made up of cell component and hyaluronic acid and preparation method thereof, but in the filler
2.0-30 mg/ml contents are seldom, it is easy to which hyaluronic acid is degraded in the short time, and injects the initial stage and face cell
Secrete the risk that a certain amount of collagen does not have filling and produces filling failure very little.Chinese specially CN2014107181008 is disclosed
The medical composition of fat stem cell and hyaluronic acid composition.Volume should keep steady to composition as moulding filling in vivo
It is fixed, the effect of moulding beauty can be just played, volume increase illustrates that moulding failure or injection have very big risk of failure.
In terms of some difficult diseases treatments, stem cell is injected into human body, passes through self targeting of Multifunction activated cell
Sexual function is accurate to up to corresponding damaged organ and tissue, with reach repair, substitute aging, lesion cell, Reconstruction of The Function is just
The purpose of normal cell and tissue, so that disease obtains treatment fundamentally.Existing research finds report, and stem cell can be controlled
Some great difficult diseases are treated, as cancer, diabetes, leukaemia, liver and kidney failure, the nervous system disease, and cartilage are damaged
Wound, it is arthritic repair, the lubrication of articular cavity etc..Stem cell transplantation at present is directly transplanting stem cell, is often obtained in vitro
Enough to after the stem cell of quantity and form, must even be implanted in patient's hand within a few hours within one day, otherwise stem cell meeting
Excessively break up and aging, therefore stem cell preserves transport and pot-life by severely restricts, can not industrialization.
It is very necessary to develop a kind of composition gels for the problem of overcoming current stem cell application to exist.
The content of the invention
The present invention, which provides a kind of composition gels, mainly includes Biodegradable material gel and stem cell composition, stem cell
Wrapped up by Biodegradable material gel.
Biodegradable material gel forms one layer of protective barrier in stem cell periphery, protects stem cell existence micro-loop
Border.
Biodegradable material gel includes free gel and cross-linked gel.Free gel refers to Biodegradable material
The gel formed in physiological saline, water for injection or the isotonic phosphate buffer of neutral physiological is dissolved in, without crosslinking agent.Crosslinking
Gel refers under certain conditions with after cross-linking agents, with phosphatizings such as physiological saline, water for injection or neutral physiologicals
It is neutral gel that acid buffer, which is eluted to pH,.The neutral isotonic phosphate buffer of physiological refer to by Na2HPO4, NaH2PO4 and
The pH value that NaCl is formed or Na2HPO4, KH2PO4 and NaCl composition are formed is 6.5-7.5, osmotic pressure 280-320mOsmol/L
Solution.The degree of cross linking refers to that Biodegradable material monomer combines the percentage of a cross-linker molecules, uses Biodegradable material
The mol ratio of monomer and crosslinking agent calculates.
Composition gels maintain the state of a balance in filling region volume after being implanted in vivo, by the differentiation of stem cell
Propagation makes up the space that hyaluronic acid is degraded, i.e. composition gels change but the composition gels in filling region in itself
Volume size keep invariable, as high Biodegradable material is gradually degraded, and the gradual Proliferation, Differentiation shape of stem cell
Cheng Xin tissue, process are in a relative equilibrium or close state all the time, and final result is biological in composition gels
Degradation material is completely degraded, and new tissue is formed by the Proliferation, Differentiation of stem cell and is replaced, permanent so as to play
Moulding and filling effect, so moulding and filling can just play permanent beauty.
The present invention has found by studying, can be with control composition by the granular size of composition gels, stem cell population
The overall performance of gel.
It is composition gels particle size maintaining the principal element that composition gels degraded balances.Composition gels are in body
Interior degraded is directly related with its particle size.But the size of particle diameter is related to propulsive force during injection, and propulsive force size
The comfort level or experience sense of user during composition gels injection can be influenceed：Particle diameter is bigger, and degradation cycle is longer, and pushing force is got over
Greatly, comfort level is poorer；Particle diameter is smaller, and degradation cycle is shorter, and pushing force is smaller, and comfort level is better.Therefore, it is necessary to be coagulated in composition
Seek a balance between micelle footpath and degradation property, according to different purposes, present composition gel particle size range is 25-
1200 μm or 30-1000 μm or 35-800 μm, 40-700 μm or 50-600 μm is can also be, recommended range is
80-500 μm or 100-400 μm, preferably 120-350 μm or 150-300 μm, optimum grain-diameter scope be 160-250 μm or
180-200μm。
Influence composition gels degraded it is also related to the molecular size range of its Biodegradable material, typically by be crosslinked come
Increase the molecular weight of Biodegradable material, the degree of cross linking is the important indicator of derivative degraded speed.The degree of cross linking is bigger, illustrates to hand over
Connection is more abundant, degradation cycle is longer；The degree of cross linking is smaller, crosslinking less, degradation cycle it is shorter.The present invention is typically chosen macromolecule
Biodegradable material, or crosslinking Biodegradable material.The degree of cross linking scope of present composition gel is 1%-
25% or 2%-20% either 3%-15% or 5%-12% or 6%-10%, recommend 7%-9%.
The free gel and stem cell that present composition gel can be formed mainly by Biodegradable material form,
Can be made up of cross-linked gel that Biodegradable material is formed and stem cell, can also by Biodegradable material solution, hand over
Connection gel and stem cell combine.In the present invention, cross-linked gel and Biodegradable material solution proportion scope are 1:49-
49:1 (W/W), can be 1:24-24:1 (W/W) or 1:9-9:1 (W/W), can also be 1:8-8:1 (W/W) or 1:7-7:
1 (W/W), the scope of recommendation is 1:5-5:1(W/W)1:4-4:1 (W/W), preferable scope are 1:3-3:1 (W/W) or 3:7-
7:3 (W/W), optimized scope 1:2-2:1 (W/W) or 1:1-1:1.5 (W/W), other are that suitable ratio meets think of of the present invention
Want to fall within invention scope of the invention.
In the present invention, the Biodegradable material of composition gels is by one or more combination structures in llowing group of materials
Into：Poly- carboxymethyl cellulose, alginate, hydroxypropyl methyl cellulose, carboxymethyl cellulose, ethylhydroxyethylcellulose, hydroxyl
Alkylcellulose, alkylcellulose, PLA, microcrystalline cellulose, poly lactic-co-glycolic acid, dextrin, HES, hydroxyl second
Base enclosure glycan, chitosan, hyaluronic acid, collagen, gelatin, and the derivative of hyaluronic acid, collagen, gelatin, it is excellent
Select alginate, Sodium Hyaluronate and its derivative, chitosan, collagen and its derivative, hydroxyethyl chitosan.The present invention
In, the scope of hyaluronic acid mean molecule quantity is 0.2-4.0MDa or 0.4-3.0MDa or 0.5-2.0MDa, is recommended
Can be 0.6-1.5MDa or 0.7-1.2MDa, preferably 0.8-1.1MDa or 0.9-1.0MDa.
In the present invention, the content range of the Biodegradable material in composition gels is 5-150mg/ml, can also
It is 10-120mg/ml or 15-100mg/ml, can also be 20-80mg/ml or 25-70mg/ml, recommends 30-60mg/ml
Or 35-55mg/ml, preferably 40-50mg/ml.
In the present invention, the stem cell of composition gels is thin including umbilical cord mesenchymal stem cells, fat stem cell, nerve cord
Born of the same parents, corium are into fiber stem cell one or more of which.Because umbilical cord mesenchymal stem cells raw material supply is more abundant, preferred navel
Band mescenchymal stem cell, it can also be that market is bought that can make extraction acquisition by oneself, and specific this is not limited by the present invention.Stem cell
There are differentiation of self and value-added ability, therefore, the concentration of stem cells of composition gels of the invention is 1.0 × 103Individual/ml~
2.0×108Individual/ml, concentration can also be 2.0 × 103Individual/ml~1.0 × 108Individual/ml or 1.0 × 104Individual/ml~2.0 ×
107Individual/ml, the concentration of recommendation is 2.0 × 104Individual/ml~1.0 × 107Individual/ml or 1.0 × 105Individual/ml~2.0 × 106Individual/
Ml, preferable concentration are 2.0 × 105Individual/ml~1.0 × 106Individual/ml.Present invention discover that in order to maintain a lasting composition
The proportioning of gel, Biodegradable material and stem cell has a principle, i.e. composition gels particle diameter is small, and the concentration of stem cell is got over
It is high；Biodegradable material concentration is higher, and the concentration of stem cell is lower；Composition gels particle diameter is big, Biodegradable material
Concentration；The degree of cross linking of Biodegradable material is higher, and the concentration of stem cell is lower.
The present invention can come from autologous, allosome or xenogenesis for the source of stem cell, preferably autologous and xenogenic origin dry
Cell.Tissue containing stem cell is obtained from the qualified healthcare structure of tool, chooses the infectious diseases such as hepatitis, syphilis, AIDS
Detection is negative and related complication, at the same through puerpera's informed consent and sign informed consent form.Stem cell seed be from
The mechanism or unit of qualification obtain.
In order to provide certain production nutriment to stem cell, in composition gels of the invention, except main dry
Outside cell, bio-degradable gel, can with the spontaneous growth factor, salt, carbohydrate, protein ingredient, nucleic acid, vitamin,
The compositions such as antibiotic, such as basic fibroblast growth factor bFGF, EGF EGF, chondroitin, L- glutamy
Amine, calciparine, VC, VB, VE, insulin, gentamicin, as long as by the composition of this thinking addition so that stem cell growth is bred,
Belong to scope of the invention.
The storage temperature range of present composition gel can be 2-30 DEG C or 4-25 DEG C or 6-23 DEG C,
Recommended temperature range is 8-20 DEG C, preferably 15-18 DEG C.
The present invention provides the mainly composition gels including Biodegradable material and stem cell and can apply to beauty, whole
Shape, anti-ageing, repair of cartilage, articular cavity lubrication, arthritis, ulcer, burn, and cancer, diabetes, leukaemia, hepatic and renal function
In exhaustion, the nervous system disease (such as Parkinson, senile dementia) great difficult diseases preparation.
The composition gels of the present invention have the advantages of degradation cycle is lasting, stability is good, stem cell raw material sources are extensive.
Brief description of the drawings
The composition gels overall schematic of accompanying drawing 1., 1 in figure is composition gels schematic diagram, and 2 be stem cell schematic diagram,
3 be Biodegradable material gel.
Embodiment
The preparation of embodiment one, umbilical cord mesenchymal stem cells
The blood stains that fresh umbilical cord is cleaned in umbilical cord medium vessels with physiological saline；
It is transferred to after umbilical cord tissue is shredded into meat gruel shape in 50ml centrifuge tubes, often pipe 30ml；
Often pipe adds 0.25%I clostridiopetidase As, repeats after mixing, in 37 DEG C of digested 20min of isothermal vibration device；
Often pipe adds 0.25% pancreatin of same volume and continues to digest 20min, until during invisible big tissue block
Can；
Often pipe adds α-MEMs of the 30ml containing FBS and stops to digest, and removes indigested tissue, adds 3 times of PBS culture mediums,
3000rpm/min centrifuges 3min supernatant discardings, collects cell；
Add isometric α-MEM containing FBS and cell is resuspended, and to cell count, be seeded to after counting by 3 × 105
In blake bottle, 37 DEG C, 5%CO2 incubators are interior to be cultivated；
After most cell attachments, every 3 days half amounts change nutrient solution, discard non-attached cell；
Observe under inverted phase contrast microscope, after cell fusion reaches 80%, digested with 0.25% pancreatin, by 1:5 ratio
Example passage, continues amplification cultivation.
The preparation of embodiment two, fat stem cell
By in adipose tissue separating device 50ml centrifuge tubes under aseptic condition, every pipe 30ml；
Often pipe adds 0.2% isometric NTx enzyme, fully mixes, and is transferred at 37 DEG C of constant temperature oscillator and digests
30min；
After often pipe adds the 30ml termination digestion of the α-MEM containing FBS, 2 times of volume PBS culture mediums, 1500rpm/min are added
5min is centrifuged, abandons after supernatant and adds after PBS rinses repeatedly, cell is resuspended in DMEM nutrient solutions；
Be seeded in 25mm culture dishes, be placed in 37 DEG C, volume fraction be 5%CO2 incubators in cultivate；
Half amount changes liquid first after 48h, and cell growth to 75%-90% passes on when merging, and changes nutrient solution within every 3 days；
Culture medium is discarded, PBS solution 5ml is added, discards PBS solution after jog, be repeated once；2mL is added per plate
0.2% pancreatin, plate is moved into 37 DEG C of digestion 2min of incubator；
Cell is observed under inverted microscope, if kytoplasm bounces back, no longer connection is in blocks between cell, shows now cell dissociation
Appropriateness, into plate, the nutrient solution containing serum of addition 2ml/ bottles is to stop to digest；
Cell suspension moves into centrifuge tube, 1500rpm/min centrifugation 5min, abandoning supernatant, 2ml nutrient solutions is added, with drop
Gently cell suspension is made in piping and druming cell to pipe, to cell count, by 1.0 × 106/bottle, and blake bottle quantity required for calculating, to
10ml fresh cultures are added in bottle, the cell suspension of mixing is divided equally into each Tissue Culture Flask；
Make cell dispersed 3 times blake bottle jog, 37 DEG C, volume fraction be to be cultivated in 5%CO2 incubators.
Remarks：About NSC, corium into the preparation method of fiber stem cell, do not make example one by one herein, on
The preparation of stem cell may be referred to《Stem cell experiment guide》(Pei Xue great waves stem cell test guide Beijing:Science Press,
2006)、《Human stem cell culture》(Fu Leixieni, Zhang Jingbo human stem cell culture Beijing:Science Press, 2009).
Embodiment three, composition gels performance
In this experiment, the different components gelling performance of the present invention, the solvent of Biodegradable material gel be compared for
It is physiological saline, specific data are shown in Table 1.
Table 1.
As can be seen that the composition gels of the present invention, Biodegradable material concentration is bigger, composition from experimental data
Gel is more containing stem cell.
Example IV, composition gels performance
In this experiment, the different components gelling performance of the present invention, the solvent of Biodegradable material gel be compared for
For the isotonic phosphoric acid buffer of neutral physiological, specific data are shown in Table 2.
Table 2.
As can be seen that the composition gels of the present invention, the degree of cross linking of Biodegradable material is smaller, group from experimental data
Compound gel is more containing stem cell.
Embodiment five, composition gels performance
In this experiment, the composition gels being made up of cross-linked-hyaluronic acid and hyaluronic acid solution different proportion be compared for
Performance, the solvent of Biodegradable material gel is water for injection, and specific data are shown in Table 3.
Table 3.
The data of this experiment show, the composition gels that the degree of cross linking of Biodegradable material gel is high and concentration is bigger,
It is fewer containing stem cell；The composition gels that the degree of cross linking of Biodegradable material gel is lower and concentration is smaller, get over containing stem cell
It is more.
Embodiment six, composition gels degradation property and pushing force performance comparison
In this experiment, fraction compositions gel and auspicious blue No. 2, refined No. 4 degradabilities of Jordan in preceding embodiment be compared for
Energy, pushing force, are specifically shown in Table 4.
Degradation property：1g sample is loaded into 1ml centrifuge tubes, the flat intraluminal fluid face of centrifugal drying, 25 μ are then added into each pipe
L hyaluronidase solutions and 25 μ l cellulases, the effect total concentration for making enzyme is 50IU/ml.Kept with not enzyme-added, other operations
Consistent sample is reference substance.37 DEG C of constant temperature 48 hours.Each pipe is stood upside down after reaction, liquid sample is absorbed with paper, measure is residual
Stay in the example weight of bottom of the tube.By the example weight measurement result of the trial target of each sample and reference substance with theoretical residual sample
The calculating of product percentage (%).
Pushing force：Determined, tested with syringe needle, under the conditions of speed 12.5mm/min is pushed by disposable syringe
It is to be carried out under 23 DEG C of environment；The wherein sample such as 3-1,3-4,4-3,3-7,3-9,5-3,4-6,5-4,3-11 is injected by 27G
The samples such as device syringe needle, 3-13,5-7,4-9,3-15,4-10,4-12 pass through 21G syringe needles, 3-17,5-15,4-14,4-
15th, the sample such as 5-19,5-20 passes through 16G syringe needles.
Table 4.
| Numbering | Particle diameter (μm) | Pushing force (N) | Percentage (%) |
| 3-1 | 25 | 9.5 | 73 |
| 3-4 | 40 | 10.1 | 74 |
| 4-3 | 80 | 12.4 | 78 |
| 3-7 | 100 | 11.3 | 76 |
| 3-9 | 150 | 11.4 | 77 |
| 5-3 | 180 | 12.8 | 78 |
| 4-6 | 200 | 12.8 | 82 |
| 5-4 | 200 | 14.5 | 80 |
| 3-11 | 200 | 13.7 | 80 |
| 3-13 | 300 | 10.5 | 83 |
| 5-7 | 300 | 12.8 | 84 |
| 4-9 | 350 | 10.7 | 86 |
| 3-15 | 400 | 11.2 | 86 |
| 4-10 | 400 | 12.4 | 88 |
| 4-12 | 500 | 15.7 | 89 |
| 3-17 | 600 | 11.2 | 87 |
| 5-15 | 600 | 11.5 | 87 |
| 4-14 | 700 | 12.7 | 89 |
| 4-15 | 800 | 13.2 | 91 |
| 5-19 | 1000 | 16.9 | 91 |
| 5-20 | 1200 | 19.3 | 90 |
| Auspicious blue No. 2 | - | 10.7 | 63 |
| Refined No. 4 of Jordan | - | 11.2 | 72 |
The data of this experiment show that the composition gels degradation cycle that particle diameter is big, the degree of cross linking is high is longer；Particle diameter is bigger, hands over
The pushing force of the higher composition gels of connection degree is bigger.Experimental data shows that the degradation property of present composition gel is outstanding.
Embodiment six, the stability of composition gels
In this experiment, composition gels Volume Changes and stem cell change in embodiment five be compared for.
Volume Changes and stem cell morphology change：5g sample loads to the centrifuge tube of 15ml blind nuts, 1500rpm/min from
Heart 2min, write down volume V1；Add α-MEM nutrient solutions of the 100 μ l containing 10%FBS into each pipe, 37 DEG C of constant temperature 15 days,
1500rpm/min centrifuges 2min, writes down volume V2；The form of stem cell before and after cultivating is contrasted simultaneously.
Result of the test shows that the V2 and V1 of all composition gels trial targets are consistent in this experiment or V2 is slightly lower than
V1, by stem cell morphology before and after cell observation culture, find stem cell morphology self-consistentency.Result of the test illustrates of the present invention group
Compound gel stability superior performance.
Claims (8)
1. a kind of composition gels, mainly it is made up of Biodegradable material gel and stem cell, it is characterised in that stem cell quilt
Biodegradable material gel wraps up, and the diameter of said composition gel particle is at 50-800 μm.
2. composition gels according to claim 1, it is characterised in that said composition gel storage temperature range is 2-25
℃。
3. composition gels according to claim 1, it is characterised in that it is dry thin that described stem cell includes umbilical cord mesenchyma
Born of the same parents, fat stem cell, NSC, corium are into fiber stem cell one or more of which.
4. composition gels according to claim 3, it is characterised in that the concentration of described stem cell is 1.0 × 104Individual/ml
~1.0 × 108Individual/ml.
5. composition gels according to claim 4, it is characterised in that described stem cell comes from autologous, allosome or xenogenesis.
6. composition gels according to claim 1, it is characterised in that described Biodegradable material gel is by following life
One or more compositions in Biodegradable material：Poly- carboxymethyl cellulose, alginate, hydroxypropyl methyl cellulose, carboxylic first
Base cellulose, ethylhydroxyethylcellulose, hydroxy alkyl cellulose, alkylcellulose, PLA, microcrystalline cellulose, polylactic acid-glycolic
Guanidine-acetic acid, dextrin, HES, hydroxyethyl chitosan, chitosan, hyaluronic acid, collagen, gelatin, and hyalomitome
Acid, collagen, the derivative of gelatin.
7. composition gels according to claim 6, it is characterised in that the concentration range of described Biodegradable material is
5-150mg/ml。
8. the composition gels as described in claim any one of 1-7 are in beauty, shaping, anti-ageing, repair of cartilage, articular cavity profit
Application in cunning, arthritis, ulcer, burn and great difficult diseases preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610639475.4A CN107693844A (en) | 2016-08-07 | 2016-08-07 | A kind of composition gels and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610639475.4A CN107693844A (en) | 2016-08-07 | 2016-08-07 | A kind of composition gels and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693844A true CN107693844A (en) | 2018-02-16 |
Family
ID=61168266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610639475.4A Pending CN107693844A (en) | 2016-08-07 | 2016-08-07 | A kind of composition gels and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693844A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108472224A (en) * | 2016-01-27 | 2018-08-31 | 株式会社资生堂 | α gel-formings composition and α gel combinations |
| CN109125806A (en) * | 2018-08-29 | 2019-01-04 | 广东克瑞斯普生物科技有限公司 | A kind of subcutaneous injection stem cell microsphere gel compound and its application |
| CN112316147A (en) * | 2019-08-01 | 2021-02-05 | 成都夸常奥普医疗科技有限公司 | Pharmaceutical composition comprising a semi-fluid of tissue cells and an active ingredient and process for preparing the composition |
| CN114796621A (en) * | 2022-03-08 | 2022-07-29 | 朱文敏 | Composite biological material and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101195044A (en) * | 2007-12-29 | 2008-06-11 | 中国人民解放军第四军医大学 | Tissue engineered fine particle tissue and method for preparing the same |
| CN101828937A (en) * | 2009-03-13 | 2010-09-15 | 王影 | Method for reshaping and beautifying by using tissue engineering fat regeneration technology |
| CN101993853A (en) * | 2009-08-13 | 2011-03-30 | 清华大学 | Injection type vascularized adipose tissue and construction method thereof |
| CN103571792A (en) * | 2012-07-25 | 2014-02-12 | 中国科学院大连化学物理研究所 | Method for in-vitro amplification of tumor stem cells |
| CN103648507A (en) * | 2010-12-30 | 2014-03-19 | 人类起源公司 | Methods for cryopreserving and encapsulating cells |
| CN104127884A (en) * | 2014-07-14 | 2014-11-05 | 云南省第一人民医院 | Rheumatoid arthritis treatment microcapsule and preparation method thereof |
| KR101472045B1 (en) * | 2013-08-16 | 2014-12-23 | 단국대학교 산학협력단 | Core-shell fibrous cell carrier and composition for regeneration of osseous tissue or cartilage tissue comprising the same |
| CN105796600A (en) * | 2016-04-28 | 2016-07-27 | 博雅干细胞科技有限公司 | Method for treating osteoarthritis by stem cells and composition |
-
2016
- 2016-08-07 CN CN201610639475.4A patent/CN107693844A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101195044A (en) * | 2007-12-29 | 2008-06-11 | 中国人民解放军第四军医大学 | Tissue engineered fine particle tissue and method for preparing the same |
| CN101828937A (en) * | 2009-03-13 | 2010-09-15 | 王影 | Method for reshaping and beautifying by using tissue engineering fat regeneration technology |
| CN101993853A (en) * | 2009-08-13 | 2011-03-30 | 清华大学 | Injection type vascularized adipose tissue and construction method thereof |
| CN103648507A (en) * | 2010-12-30 | 2014-03-19 | 人类起源公司 | Methods for cryopreserving and encapsulating cells |
| CN103571792A (en) * | 2012-07-25 | 2014-02-12 | 中国科学院大连化学物理研究所 | Method for in-vitro amplification of tumor stem cells |
| KR101472045B1 (en) * | 2013-08-16 | 2014-12-23 | 단국대학교 산학협력단 | Core-shell fibrous cell carrier and composition for regeneration of osseous tissue or cartilage tissue comprising the same |
| CN104127884A (en) * | 2014-07-14 | 2014-11-05 | 云南省第一人民医院 | Rheumatoid arthritis treatment microcapsule and preparation method thereof |
| CN105796600A (en) * | 2016-04-28 | 2016-07-27 | 博雅干细胞科技有限公司 | Method for treating osteoarthritis by stem cells and composition |
Non-Patent Citations (2)
| Title |
|---|
| 方亮: "《药用高分子材料》", 31 August 2015 * |
| 王忆娟: "作为细胞微载体的明胶缓释微球的制备及其性能研究", 《陕西师范大学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108472224A (en) * | 2016-01-27 | 2018-08-31 | 株式会社资生堂 | α gel-formings composition and α gel combinations |
| CN108472224B (en) * | 2016-01-27 | 2021-05-07 | 株式会社资生堂 | Composition for forming alpha gel and alpha gel composition |
| CN109125806A (en) * | 2018-08-29 | 2019-01-04 | 广东克瑞斯普生物科技有限公司 | A kind of subcutaneous injection stem cell microsphere gel compound and its application |
| CN112316147A (en) * | 2019-08-01 | 2021-02-05 | 成都夸常奥普医疗科技有限公司 | Pharmaceutical composition comprising a semi-fluid of tissue cells and an active ingredient and process for preparing the composition |
| CN114796621A (en) * | 2022-03-08 | 2022-07-29 | 朱文敏 | Composite biological material and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| García-Gareta et al. | Decellularised scaffolds: just a framework? Current knowledge and future directions | |
| Chen et al. | PCL-MECM-based hydrogel hybrid scaffolds and meniscal fibrochondrocytes promote whole meniscus regeneration in a rabbit meniscectomy model | |
| Bakhshandeh et al. | Tissue engineering; strategies, tissues, and biomaterials | |
| Kajbafzadeh et al. | Determining the optimal decellularization and sterilization protocol for preparing a tissue scaffold of a human-sized liver tissue | |
| Chen et al. | Injectable self-crosslinking HA-SH/Col I blend hydrogels for in vitro construction of engineered cartilage | |
| Lee et al. | Engineered cartilage covered ear implants for auricular cartilage reconstruction | |
| Tang et al. | Chondrocyte-laden GelMA hydrogel combined with 3D printed PLA scaffolds for auricle regeneration | |
| Yadav et al. | In vitro chondrogenesis with lysozyme susceptible bacterial cellulose as a scaffold | |
| Meretoja et al. | Articular chondrocyte redifferentiation in 3D co-cultures with mesenchymal stem cells | |
| Azzena et al. | Autologous platelet-rich plasma as an adipocyte in vivo delivery system: case report | |
| CN103877616B (en) | A kind of cartilage tissue engineered recovery support and preparation method thereof | |
| KR101814440B1 (en) | Method for preparation of bead-type chondrocyte therapeutic agent | |
| Santos et al. | Culture of mesenchymal stem cells derived from equine synovial membrane in alginate hydrogel microcapsules | |
| CN107693844A (en) | A kind of composition gels and application | |
| CN110354311A (en) | Extracellular matrix composite transparent matter acid gel and preparation method thereof, application and biomaterial | |
| Chen et al. | Adipose-derived stem cells modified genetically in vivo promote reconstruction of bone defects | |
| CN104667348B (en) | A kind of Pharmaceutical composition containing sodium alginate and preparation method thereof | |
| Dadgar et al. | Cartilage tissue engineering using injectable functionalized Demineralized Bone Matrix scaffold with glucosamine in PVA carrier, cultured in microbioreactor prior to study in rabbit model | |
| Yang et al. | Construction of microunits by adipose-derived mesenchymal stem cells laden with porous microcryogels for repairing an acute achilles tendon rupture in a rat model | |
| Wang et al. | Chondrocyte-laden gelatin/sodium alginate hydrogel integrating 3D printed PU scaffold for auricular cartilage reconstruction | |
| Han et al. | Study on bioactive PEGDA/ECM hybrid bi-layered hydrogel scaffolds fabricated by electro-writing for cartilage regeneration | |
| Sun et al. | Advances in the treatment of partial-thickness cartilage defect | |
| CN104056304A (en) | Growth-factor-chitosan-microsphere loaded DBM support joint cartilage repairing material | |
| Schwarz et al. | Characterization of adipose-derived equine and canine mesenchymal stem cells after incubation in agarose-hydrogel | |
| Wang et al. | Gelatin-based hydrogels for controlled cell assembly |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180216 |
|
| WD01 | Invention patent application deemed withdrawn after publication |